Roche anti-cancer drug Atezolizumab gets CDSCO panel nod for Metastatic Triple Negative Breast Cancer

Based on the justification provided by the pharmaceutical giant Roche, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has approved Roche's anticancer drug Atezolizumab for continuation of indication of metastatic triple negative breast cancer.

However, the said indication of metastatic triple negative breast cancer came inline with European Medicines Agency (EMA) approval namely "Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease".

For more details, check out the full story on the link below:

CDSCO Panel Nod To Roche Anti Cancer Drug Atezolizumab For Metastatic Triple Negative Breast Cancer